Cargando…

Co-creation of patient engagement quality guidance for medicines development: an international multistakeholder initiative

INTRODUCTION: Meaningful patient engagement (PE) can enhance medicines’ development. However, the current PE landscape is fragmentary and lacking comprehensive guidance. METHODS: We systematically searched for PE initiatives (SYNaPsE database/publications). Multistakeholder groups integrated these w...

Descripción completa

Detalles Bibliográficos
Autores principales: Deane, Katherine, Delbecque, Laure, Gorbenko, Oleksandr, Hamoir, Anne Marie, Hoos, Anton, Nafria, Begonya, Pakarinen, Chi, Sargeant, Ify, Richards, Dawn P, Skovlund, Soren Eik, Brooke, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792320/
https://www.ncbi.nlm.nih.gov/pubmed/31645992
http://dx.doi.org/10.1136/bmjinnov-2018-000317
_version_ 1783459125645017088
author Deane, Katherine
Delbecque, Laure
Gorbenko, Oleksandr
Hamoir, Anne Marie
Hoos, Anton
Nafria, Begonya
Pakarinen, Chi
Sargeant, Ify
Richards, Dawn P
Skovlund, Soren Eik
Brooke, Nicholas
author_facet Deane, Katherine
Delbecque, Laure
Gorbenko, Oleksandr
Hamoir, Anne Marie
Hoos, Anton
Nafria, Begonya
Pakarinen, Chi
Sargeant, Ify
Richards, Dawn P
Skovlund, Soren Eik
Brooke, Nicholas
author_sort Deane, Katherine
collection PubMed
description INTRODUCTION: Meaningful patient engagement (PE) can enhance medicines’ development. However, the current PE landscape is fragmentary and lacking comprehensive guidance. METHODS: We systematically searched for PE initiatives (SYNaPsE database/publications). Multistakeholder groups integrated these with their own PE expertise to co-create draft PE Quality Guidance which was evaluated by public consultation. Projects exemplifying good PE practice were identified and assessed against PE Quality Criteria to create a Book of Good Practices (BOGP). RESULTS: Seventy-six participants from 51 organisations participated in nine multistakeholder meetings (2016–2018). A shortlist of 20relevant PE initiatives (from 170 screened) were identified. The co-created INVOLVE guidelines provided the main framework for PE Quality Guidance and was enriched with the analysis of the PE initiatives and the PE expertise of stakeholders. Seven key PE Quality Criteria were identified. Public consultation yielded 67 responses from diverse backgrounds. The PE Quality Guidance was agreed to be useful for achieving quality PE in practice, understandable, easy to use, and comprehensive. Overall, eight initiatives from the shortlist and from meeting participants were selected for inclusion in the BOGP based on demonstration of PE Quality Criteria and willingness of initiative owners to collaborate. DISCUSSION: The PE Quality Guidance and BOGP are practical resources which will be continually updated in response to user feedback. They are not prescriptive, but rather based on core principles, which can be applied according to the unique needs of each interaction and initiative. Implementation of the guidance will facilitate improved and systematic PE across the medicines’ development lifecycle.
format Online
Article
Text
id pubmed-6792320
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-67923202019-10-21 Co-creation of patient engagement quality guidance for medicines development: an international multistakeholder initiative Deane, Katherine Delbecque, Laure Gorbenko, Oleksandr Hamoir, Anne Marie Hoos, Anton Nafria, Begonya Pakarinen, Chi Sargeant, Ify Richards, Dawn P Skovlund, Soren Eik Brooke, Nicholas BMJ Innov Health IT, systems and process innovations INTRODUCTION: Meaningful patient engagement (PE) can enhance medicines’ development. However, the current PE landscape is fragmentary and lacking comprehensive guidance. METHODS: We systematically searched for PE initiatives (SYNaPsE database/publications). Multistakeholder groups integrated these with their own PE expertise to co-create draft PE Quality Guidance which was evaluated by public consultation. Projects exemplifying good PE practice were identified and assessed against PE Quality Criteria to create a Book of Good Practices (BOGP). RESULTS: Seventy-six participants from 51 organisations participated in nine multistakeholder meetings (2016–2018). A shortlist of 20relevant PE initiatives (from 170 screened) were identified. The co-created INVOLVE guidelines provided the main framework for PE Quality Guidance and was enriched with the analysis of the PE initiatives and the PE expertise of stakeholders. Seven key PE Quality Criteria were identified. Public consultation yielded 67 responses from diverse backgrounds. The PE Quality Guidance was agreed to be useful for achieving quality PE in practice, understandable, easy to use, and comprehensive. Overall, eight initiatives from the shortlist and from meeting participants were selected for inclusion in the BOGP based on demonstration of PE Quality Criteria and willingness of initiative owners to collaborate. DISCUSSION: The PE Quality Guidance and BOGP are practical resources which will be continually updated in response to user feedback. They are not prescriptive, but rather based on core principles, which can be applied according to the unique needs of each interaction and initiative. Implementation of the guidance will facilitate improved and systematic PE across the medicines’ development lifecycle. BMJ Publishing Group 2019-01 2019-03-02 /pmc/articles/PMC6792320/ /pubmed/31645992 http://dx.doi.org/10.1136/bmjinnov-2018-000317 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Health IT, systems and process innovations
Deane, Katherine
Delbecque, Laure
Gorbenko, Oleksandr
Hamoir, Anne Marie
Hoos, Anton
Nafria, Begonya
Pakarinen, Chi
Sargeant, Ify
Richards, Dawn P
Skovlund, Soren Eik
Brooke, Nicholas
Co-creation of patient engagement quality guidance for medicines development: an international multistakeholder initiative
title Co-creation of patient engagement quality guidance for medicines development: an international multistakeholder initiative
title_full Co-creation of patient engagement quality guidance for medicines development: an international multistakeholder initiative
title_fullStr Co-creation of patient engagement quality guidance for medicines development: an international multistakeholder initiative
title_full_unstemmed Co-creation of patient engagement quality guidance for medicines development: an international multistakeholder initiative
title_short Co-creation of patient engagement quality guidance for medicines development: an international multistakeholder initiative
title_sort co-creation of patient engagement quality guidance for medicines development: an international multistakeholder initiative
topic Health IT, systems and process innovations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792320/
https://www.ncbi.nlm.nih.gov/pubmed/31645992
http://dx.doi.org/10.1136/bmjinnov-2018-000317
work_keys_str_mv AT deanekatherine cocreationofpatientengagementqualityguidanceformedicinesdevelopmentaninternationalmultistakeholderinitiative
AT delbecquelaure cocreationofpatientengagementqualityguidanceformedicinesdevelopmentaninternationalmultistakeholderinitiative
AT gorbenkooleksandr cocreationofpatientengagementqualityguidanceformedicinesdevelopmentaninternationalmultistakeholderinitiative
AT hamoirannemarie cocreationofpatientengagementqualityguidanceformedicinesdevelopmentaninternationalmultistakeholderinitiative
AT hoosanton cocreationofpatientengagementqualityguidanceformedicinesdevelopmentaninternationalmultistakeholderinitiative
AT nafriabegonya cocreationofpatientengagementqualityguidanceformedicinesdevelopmentaninternationalmultistakeholderinitiative
AT pakarinenchi cocreationofpatientengagementqualityguidanceformedicinesdevelopmentaninternationalmultistakeholderinitiative
AT sargeantify cocreationofpatientengagementqualityguidanceformedicinesdevelopmentaninternationalmultistakeholderinitiative
AT richardsdawnp cocreationofpatientengagementqualityguidanceformedicinesdevelopmentaninternationalmultistakeholderinitiative
AT skovlundsoreneik cocreationofpatientengagementqualityguidanceformedicinesdevelopmentaninternationalmultistakeholderinitiative
AT brookenicholas cocreationofpatientengagementqualityguidanceformedicinesdevelopmentaninternationalmultistakeholderinitiative